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use of a highly selected collection of isolates, all of
which had a low penicillin MIC according to
Vitek 2. In contrast to previous studies, a molec-
ular method was used as the reference standard.
Pitka¨la¨ et al. [9] also used PCR detection of blaZ as
the reference standard, but only with bovine
S. aureus isolates.
In conclusion, the results of this study discour-
age the use of nitrocefin tests or the starch–iodine
plate method as additional assays for isolates with
penicillin MICs of 0.06 or 0.12 mg ⁄L according to
the Vitek 2 system. Higher sensitivities were
found for penicillin zone-edge determination and
the cloverleaf assay, but it might be insufficient to
report an isolate from a serious infection as
penicillin-sensitive without performing a PCR to
detect blaZ.
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ABSTRACT
This study determined the types of AmpC
enzymesproduced byKlebsiella pneumoniae isolates
resistant to third-generation cephalosporins and
the clonality of these isolates. The presence of
AmpC enzymes was identified by cephalosporin–
cloxacillin synergy tests. Genes encoding AmpC
enzymes were characterised by PCR and sequenc-
ing. Pulsed-field gel electrophoresis (PFGE) was
used to type the isolates. Fifteen K. pneumoniae
isolates were positive for blaAmpC, 13 were positive
for blaACC-1 and two were positive for blaDHA-1.
Production of the DHA-1 enzyme was inducible.
The ampR gene was identified upstream of the
blaDHA-1 gene. PFGE demonstrated the polyclonal
origin of the isolates carrying blaACC-1.
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AmpC b-lactamases are being reported increas-
ingly among Klebsiella pneumoniae isolates world-
wide. However, the prevalence of AmpC-type
b-lactamases among resistant K. pneumoniae iso-
lates varies regionally, from 8.5% in the USA [1] to
55% in the UK [2]. Detection of AmpC-mediated
resistance remains challenging, and there are cur-
rently no CLSI guidelines regarding the method-
ology for detection of this type of resistance. Few
data are available concerning the identification and
epidemiology of AmpC enzymes in K. pneumoniae
in Ireland [2]. The present prospective study
determined the prevalence and types of AmpC
enzymes among K. pneumoniae isolates resistant to
third-generation cephalosporins, as well as the
epidemiology of K. pneumoniae isolates carrying
plasmid-mediated AmpC b-lactamases.
Non-replicate isolates ofK. pneumoniae, resistant
to one or more of the third-generation cephalospo-
rins ceftazidime, cefotaxime and ⁄ or cefpodoxime,
were collected prospectively from April 2005 to
March 2007. Susceptibilities were determined by
disk-diffusion, by Etest (AB Biodisk, Solna, Swe-
den), by the agar dilution method according to
CLSI guidelines [3], and by using the Vitek 2 GNI
susceptibility test system (bioMe´rieux, Marcy
l’Etoile, France) [3]. Identification of isolates was
according to the Vitek GNI identification system
(bioMe´rieux). Screening for AmpC b-lactamases
was performed by measuring cefotaxime and
ceftazidime MICs by Etest and Vitek 2 on both
Mueller–Hinton medium and Mueller–Hinton
medium containing cloxacillin 100 mg ⁄L. A
‡two-fold reduction in the MIC in the presence of
cloxacillin suggested the presence of an AmpC b-
lactamase. Induction ofAmpCwas inferred if there
was truncation in the zone around a cefotaxime 30-
lg disk adjacent to a cefoxitin 30-lg disk.
Genes encoding acquired AmpC enzymes
were identified using a multiplex PCR assay
[4]. Subsequent PCR amplification and sequenc-
ing was performed using primers 5¢-TTTTCT
TTTGCATGCGGATT (forward) and 5¢-ACAG
GGCGTGCTGTAATACC (reverse) for acc genes,
and primers 5¢-ACACTGATTTCCGCTCTGCT
(forward) and 5¢-ACAATCGCCACCTGTTTTTC
(reverse) for dha genes. The forward primer for
detection of the ampR gene upstream of the dha-1
gene was 5¢-CAGGGTAAAGCGGTGAACAT.
The nucleotide sequences reported in this study
appear in GenBank under accession numbers
EF554600 (acc-1) and EF633612 (ampR and dha-1).
Integron analysis was performed according to
Levesque et al. [5].
Isolates were genotyped by pulsed-field gel
electrophoresis using a CHEF DR II system (Bio-
Rad, Hemel Hempstead, UK) following digestion
of intact bacterial DNA with XbaI [6]. The relat-
edness among isolates was calculated using the
Dice coefficient, followed by cluster analysis
using the unweighted pair-group method with
arithmetic averages.
Of 500 clinical isolates of K. pneumoniae, 32
showed increased resistance to at least one oxy-
imino-b-lactam. Fifteen (48%) of these isolates
were selected as possible AmpC producers. One
isolate co-produced a class A extended-spectrum
b-lactamase according to phenotypic tests (data
not shown). The remaining 17 isolates also had
phenotypes consistent with class A extended-
spectrum b-lactamase production. The 15 selected
isolates were shown to be AmpC-positive accord-
ing to the multiplex PCR, with 13 being positive
for ACC-type b-lactamases and two for DHA-
type b-lactamases. The latter two isolates showed
inducible resistance. Nucleotide sequencing
revealed that the 13 blaACC genes were identical,
and that there was 100% concordance with the
known K. pneumoniae blaACC-1 sequence (GenBank
accession no. AJ133121). The sequences of the two
blaDHA genes were also identical and had 100%
concordance with the known blaDHA-1 gene
of K. pneumoniae (GenBank accession
no. DQ478716). In addition, ampR was found
upstream of the blaDHA-1 gene in both isolates.
According to PCR results, the two isolates
expressing DHA-1 and one isolate expressing
ACC-1 were positive for an integron.
Susceptibility data are summarised in Table 1.
All 15 isolates were susceptible to carbapenems
and cefepime. High-level cefoxitin resistance was
found only in the two isolates that produced
DHA-1. All 15 isolates were resistant to
co-amoxyclav, but most were susceptible to
amikacin, gentamicin and ciprofloxacin.
Cluster analysis of the 13 isolates producing
ACC-1 suggested three clusters of isolates with
varying levels of relatedness: cluster 1 contained
two identical isolates (7 and 9) with no band
differences; cluster 2 contained two isolates (6 and
14) with four band differences; and cluster 3 con-
tained two isolates (3 and 10) with six band differ-
ences. These three clusters were not related to each
other. The remaining isolates were all unrelated.
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In conclusion, the present study identified two
types of plasmidic AmpC enzymes, ACC-1 and
DHA-1. While the two isolates producing DHA-1
constitute the first report of inducible plasmidic
AmpC enzymes among K. pneumoniae isolates in
Ireland, the main acquired AmpC enzyme was
ACC-1. This enzyme was identified in 48%
of K. pneumoniae isolates, compared to a frequency
of 25% in a recent study in theUK and Irelandwith
similar selection criteria [2]. The findings are
similar to other reports from France and Spain
[7,8], which suggests that ACC-1 is spreading
within Europe. Most (9 ⁄ 13) of the ACC-1-produc-
ing K. pneumoniae isolates were susceptible to
cefoxitin, which is unusual, as cefoxitin resistance,
combinedwith reduced susceptibility to oxyimino-
b-lactams, is indicative of class C b-lactamase
production [9]. K. pneumoniae isolates susceptible
to cefoxitin and cefepime, but with decreased
susceptibility to ceftazidime and ⁄ or cefotaxime,
are suggestive of plasmidic AmpC production and
should therefore undergo confirmatory testing.
The pulsed-field gel electrophoresis data sug-
gested that the incidence of transferable AmpC-
mediated resistance within the hospital was the
result of transfer of a mobile element rather than
the spread of a single clone. There is a need for
continuous surveillance of the prevalence and
evolution of these enzymes in Ireland.
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(100 mg/L) Fox Cftx Tzp Mem Ipm Etp Fep Tem Cip Mox Gen
1 >32 >32 32 16 4 >32 32 0.064 0.125 0.064 2 8 1 0.5 64
2 16 0.25 16 0.25 >256 2 8 0.25 0.25 0.5 <1 2 2 2 1
3 >32 2 >256 12 16 >32 128 0.064 0.25 0.125 <1 8 >32 16 2
4 >32 4 >256 24 8 >32 128 0.125 0.125 0.125 <1 8 16 8 2
5 >32 8 >256 24 64 >32 256 0.064 0.25 0.25 <1 16 0.5 0.5 1
6 8 1 32 4 8 8 16 0.064 0.25 0.064 <1 8 2 2 2
7 4 2 32 4 8 8 16 0.064 0.25 0.064 <1 8 4 2 2
8 4 2 32 8 8 16 256 0.064 0.125 0.064 <1 8 2 0.5 2
9 8 1 64 4 8 8 16 0.064 0.25 0.064 <1 8 2 2 2
10 4 0.25 16 1 4 4 16 0.25 0.25 0.016 <1 4 0.5 0.5 2
11 16 4 32 8 >256 2 256 0.5 0.25 0.5 <1 16 >32 >32 2
12 >32 8 64 16 64 32 32 0.125 0.125 0.125 <1 16 16 8 1
13 32 4 64 16 16 16 128 0.064 0.125 0.125 <1 8 8 8 64
14 8 1 32 4 4 8 32 0.25 0.25 0.016 <1 4 0.5 0.5 2
15 8 2 32 4 8 8 128 0.125 0.25 0.064 <1 8 0.5 0.5 1
Gen, gentamicin; Cip, ciprofloxacin; Tzp, piperacillin–tazobactam; Ipm, imipenem; Mem, meropenem; Etp, ertapenem; Fox, cefoxitin; Cftx, ceftriaxone; Mox, moxifloxacin;
Tem, temocillin; Ctx, cefotaxime; Caz, ceftazidime; Fep, cefepime; Clox, cloxacillin.
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